Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
Front Physiol ; 14: 1231793, 2023.
Article in English | MEDLINE | ID: mdl-37869717

ABSTRACT

Introduction: We aimed to demonstrate non-invasive measurements of regional oxygen extraction fraction (OEF) from quantitative BOLD MRI modeling at baseline and after pharmacological vasodilation. We hypothesized that OEF decreases in response to vasodilation with acetazolamide (ACZ) in healthy conditions, reflecting compensation in regions with increased cerebral blood flow (CBF), while cerebral metabolic rate of oxygen (CMRO2) remained unchanged. We also aimed to assess the relationship between OEF and perfusion in the default mode network (DMN) regions that have shown associations with vascular risk factors and cerebrovascular reactivity in different neurological conditions. Material and methods: Eight healthy subjects (47 ± 13 years, 6 female) were scanned on a 3 T scanner with a 32-channel head coil before and after administration of 15 mg/kg ACZ as a pharmacological vasodilator. The MR imaging acquisition protocols included: 1) A Gradient Echo Slice Excitation Profile Imaging Asymmetric Spin Echo scan to quantify OEF, deoxygenated blood volume, and reversible transverse relaxation rate (R2 ') and 2) a multi-post labeling delay arterial spin labeling scan to measure CBF. To assess changes in each parameter due to vasodilation, two-way t-tests were performed for all pairs (baseline versus vasodilation) in the DMN brain regions with Bonferroni correction for multiple comparisons. The relationships between CBF versus OEF and CBF versus R2' were analyzed and compared across DMN regions using linear, mixed-effect models. Results: During vasodilation, CBF significantly increased in the medial frontal cortex (P=0.004), posterior cingulate gyrus (pCG) (P=0.004), precuneus cortex (PCun) (P=0.004), and occipital pole (P=0.001). Concurrently, a significant decrease in OEF was observed only in the pCG (8.8%, P=0.003) and PCun (8.7%,P=0.001). CMRO2 showed a trend of increased values after vasodilation, but these differences were not significant after correction for multiple comparisons. Although R2' showed a slightly decreasing trend, no statistically significant changes were found in any regions in response to ACZ. The CBF response to ACZ exhibited a stronger negative correlation with OEF (ß=-0.104±0.027; t=-3.852,P<0.001), than with R2' (ß=-0.016±0.006; t=-2.692,P=0.008). Conclusion: Quantitative BOLD modeling can reliably measure OEF across multiple physiological conditions and captures vascular changes with higher sensitivity than R2' values. The inverse correlation between OEF and CBF across regions in DMN, suggests that these two measurements, in response to ACZ vasodilation, are reliable indicators of tissue health in this healthy cohort.

2.
PLoS One ; 14(5): e0216596, 2019.
Article in English | MEDLINE | ID: mdl-31067263

ABSTRACT

We do not have a full understanding of the mechanisms underlying plasticity in the human brain. Mouse models have well controlled environments and genetics, and provide tools to help dissect the mechanisms underlying the observed responses to therapies devised for humans recovering from injury of ischemic nature or trauma. We aimed to detect plasticity following learning of a unilateral reaching movement, and relied on MRI performed with a rapid structural protocol suitable for in vivo brain imaging, and a longer diffusion tensor imaging (DTI) protocol executed ex vivo. In vivo MRI detected contralateral volume increases in trained animals (reachers), in circuits involved in motor control, sensory processing, and importantly, learning and memory. The temporal association area, parafascicular and mediodorsal thalamic nuclei were also enlarged. In vivo MRI allowed us to detect longitudinal effects over the ~25 days training period. The interaction between time and group (trained versus not trained) supported a role for the contralateral, but also the ipsilateral hemisphere. While ex vivo imaging was affected by shrinkage due to the fixation, it allowed for superior resolution and improved contrast to noise ratios, especially for subcortical structures. We examined microstructural changes based on DTI, and identified increased fractional anisotropy and decreased apparent diffusion coefficient, predominantly in the cerebellum and its connections. Cortical thickness differences did not survive multiple corrections, but uncorrected statistics supported the contralateral effects seen with voxel based volumetric analysis, showing thickening in the somatosensory, motor and visual cortices. In vivo and ex vivo analyses identified plasticity in circuits relevant to selecting actions in a sensory-motor context, through exploitation of learned association and decision making. By mapping a connectivity atlas into our ex vivo template we revealed that changes due to skilled motor learning occurred in a network of 35 regions, including the primary and secondary motor (M1, M2) and sensory cortices (S1, S2), the caudate putamen (CPu), visual (V1) and temporal association cortex. The significant clusters intersected tractography based networks seeded in M1, M2, S1, V1 and CPu at levels > 80%. We found that 89% of the significant cluster belonged to a network seeded in the contralateral M1, and 85% to one seeded in the contralateral M2. Moreover, 40% of the M1 and S1 cluster by network intersections were in the top 80th percentile of the tract densities for their respective networks. Our investigation may be relevant to studies of rehabilitation and recovery, and points to widespread network changes that accompany motor learning that may have potential applications to designing recovery strategies following brain injury.


Subject(s)
Brain Mapping/methods , Brain/physiology , Learning/physiology , Magnetic Resonance Imaging/methods , Motor Skills/physiology , Nerve Net/physiology , Neuronal Plasticity/physiology , Animals , Male , Mice , Mice, Inbred C57BL
3.
Neurology ; 93(1): e1-e7, 2019 07 02.
Article in English | MEDLINE | ID: mdl-31142634

ABSTRACT

OBJECTIVE: To compare the clinical characteristics and outcomes of primary intracerebral hemorrhage (ICH) with and without methamphetamine exposure. METHODS: We performed a retrospective analysis of patients diagnosed with spontaneous, nontraumatic ICH over a 3-year period between January 2013 and December 2016. Demographics, clinical measures, and outcomes were compared between ICH patients with positive methamphetamine toxicology tests vs those with negative methamphetamine toxicology tests. RESULTS: Methamphetamine-positive ICH patients were younger than methamphetamine-negative ICH patients (52 vs 67 years, p < 0.001). Patients with methamphetamine-positive ICH had higher diastolic blood pressure (115 vs 101, p = 0.003), higher mean arterial pressure (144 vs 129, p = 0.01), longer lengths of hospital (18 vs 8 days, p < 0.001) and intensive care unit (ICU) stay (10 vs 5 days, p < 0.001), required more days of IV antihypertensive medications (5 vs 3 days, p = 0.02), and had more subcortical hemorrhages (63% vs 46%, p = 0.05). The methamphetamine-positive group had better premorbid modified Rankin Scale (mRS) scores (p < 0.001) and a greater change in functional ability as measured by mRS at the time of hospital discharge (p = 0.001). In multivariate analyses, methamphetamine use predicted both hospital length of stay (risk ratio [RR] 1.54, confidence interval [CI] 1.39-1.70, p < 0.001) and ICU length of stay (RR 1.36, CI 1.18-1.56, p < 0.001), but did not predict poor outcome (mRS 4-6). CONCLUSIONS: Methamphetamine use is associated with earlier age at onset of ICH, longer hospital stays, and greater change in functional ability, but did not predict outcome.


Subject(s)
Amphetamine-Related Disorders/complications , Central Nervous System Stimulants/adverse effects , Cerebral Hemorrhage/complications , Cerebral Hemorrhage/therapy , Methamphetamine/adverse effects , Age of Onset , Aged , Amphetamine-Related Disorders/epidemiology , Amphetamine-Related Disorders/therapy , Blood Pressure , Cerebral Hemorrhage/epidemiology , Disability Evaluation , Female , Humans , Length of Stay , Male , Middle Aged , Retrospective Studies , Treatment Outcome
4.
J Stroke Cerebrovasc Dis ; 26(6): e102-e104, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28416406

ABSTRACT

Dabigatran is a direct thrombin inhibitor used to reduce the risk of stroke in patients with nonvalvular atrial fibrillation. For patients who present with an acute stroke despite dabigatran therapy, clinical data on the use of intravenous tissue plasminogen activator (IV-tPA) is limited. There is an anticipated increased risk of symptomatic intracranial hemorrhage (sICH) when using IV-tPA in patients on dabigatran therapy. In 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran. Dabigatran reversal with idarucizumab before administration of IV-tPA might reduce the risk of sICH. We report a case of a 69-year-old stroke patient on dabigatran for paroxysmal atrial fibrillation who presented with an initial National Institutes of Health Stroke Scale (NIHSS) of 12. There was no early evidence of ischemic stroke or hemorrhage on head computed tomography, and coagulation studies implied therapeutic dabigatran levels. After controlling blood pressure, dabigatran was reversed with idarucizumab, and IV-tPA was administrated beginning 197 minutes after he was last seen at his baseline. Subsequent brain magnetic resonance imaging showed 2 punctate infarcts in the left temporal lobe and occipital lobe with no evidence of hemorrhage. The patient was discharged with an NIHSS of 1. Telephone follow-up 2 months later indicated that he was at his prestroke baseline, except for a complaint of worsened short-term memory. Idarucizumab reversal of dabigatran may reduce the risk of sICH and should be considered for acute stroke patients arriving in the IV-tPA time window.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Antithrombins/therapeutic use , Blood Coagulation/drug effects , Coagulants/therapeutic use , Dabigatran/therapeutic use , Fibrinolytic Agents/administration & dosage , Stroke/drug therapy , Thrombolytic Therapy , Tissue Plasminogen Activator/administration & dosage , Administration, Intravenous , Aged , Antithrombins/adverse effects , Dabigatran/adverse effects , Diffusion Magnetic Resonance Imaging , Fibrinolytic Agents/adverse effects , Humans , Intracranial Hemorrhages/chemically induced , Intracranial Hemorrhages/prevention & control , Male , Stroke/blood , Stroke/diagnostic imaging , Stroke/etiology , Thrombolytic Therapy/adverse effects , Tissue Plasminogen Activator/adverse effects , Treatment Outcome
5.
J Vis Exp ; (109)2016 Mar 17.
Article in English | MEDLINE | ID: mdl-27023377

ABSTRACT

Stroke affecting white matter accounts for up to 25% of clinical stroke presentations, occurs silently at rates that may be 5-10 fold greater, and contributes significantly to the development of vascular dementia. Few models of focal white matter stroke exist and this lack of appropriate models has hampered understanding of the neurobiologic mechanisms involved in injury response and repair after this type of stroke. The main limitation of other subcortical stroke models is that they do not focally restrict the infarct to the white matter or have primarily been validated in non-murine species. This limits the ability to apply the wide variety of murine research tools to study the neurobiology of white matter stroke. Here we present a methodology for the reliable production of a focal stroke in murine white matter using a local injection of an irreversible eNOS inhibitor. We also present several variations on the general protocol including two unique stereotactic variations, retrograde neuronal tracing, as well as fresh tissue labeling and dissection that greatly expand the potential applications of this technique. These variations allow for multiple approaches to analyze the neurobiologic effects of this common and understudied form of stroke.


Subject(s)
Axons/pathology , Disease Models, Animal , Enzyme Inhibitors/toxicity , Nerve Degeneration/pathology , Ornithine/analogs & derivatives , Stroke/pathology , White Matter/drug effects , Animals , Axons/drug effects , Male , Mice , Mice, Inbred C57BL , Nerve Degeneration/chemically induced , Nitric Oxide Synthase Type III/antagonists & inhibitors , Ornithine/toxicity , Stroke/chemically induced , White Matter/pathology
6.
Stroke ; 46(10): 2951-60, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26294676

ABSTRACT

BACKGROUND AND PURPOSE: Data from both humans and animal models suggest that most recovery from motor impairment after stroke occurs in a sensitive period that lasts only weeks and is mediated, in part, by an increased responsiveness to training. Here, we used a mouse model of focal cortical stroke to test 2 hypotheses. First, we investigated whether responsiveness to training decreases over time after stroke. Second, we tested whether fluoxetine, which can influence synaptic plasticity and stroke recovery, can prolong the period over which large training-related gains can be elicited after stroke. METHODS: Mice were trained to perform a skilled prehension task to an asymptotic level of performance after which they underwent stroke induction in the caudal forelimb area. The mice were then retrained after a 1- or 7-day delay with and without fluoxetine. RESULTS: Recovery of prehension after a caudal forelimb area stroke was complete if training was initiated 1 day after stroke but incomplete if it was delayed by 7 days. In contrast, if fluoxetine was administered at 24 hours after stroke, then complete recovery of prehension was observed even with the 7-day training delay. Fluoxetine seemed to mediate its beneficial effect by reducing inhibitory interneuron expression in intact premotor cortex rather than through effects on infarct volume or cell death. CONCLUSIONS: There is a gradient of diminishing responsiveness to motor training over the first week after stroke. Fluoxetine can overcome this gradient and maintain maximal levels of responsiveness to training even 7 days after stroke.


Subject(s)
Behavior, Animal/drug effects , Fluoxetine/pharmacology , Motor Activity/drug effects , Motor Cortex/drug effects , Neurological Rehabilitation , Selective Serotonin Reuptake Inhibitors/pharmacology , Stroke Rehabilitation , Animals , Disease Models, Animal , Male , Mice , Motor Cortex/pathology , Motor Cortex/physiopathology , Motor Skills/drug effects , Movement/drug effects , Neuronal Plasticity/drug effects , Recovery of Function/drug effects , Stroke/pathology , Stroke/physiopathology , Time-to-Treatment
7.
Front Neurol ; 6: 156, 2015.
Article in English | MEDLINE | ID: mdl-26217302

ABSTRACT

Recent successful endovascular stroke trials have provided unequivocal support for these therapies in selected patients with large-vessel occlusive acute ischemic stroke. In this piece, we briefly review these trials and their utilization of advanced neuroimaging techniques that played a pivotal role in their success through targeted patient selection. In this context, the unique challenges and opportunity for advancement in current stroke networks' routine delivery of care created by these trials are discussed and recommendations to change current national stroke system guidelines are proposed.

8.
Brain Struct Funct ; 212(2): 133-48, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17764016

ABSTRACT

Newly generated neurons are continuously added to the olfactory epithelium and olfactory bulbs of adult mammals. Studies also report newly generated neurons in the piriform cortex, the primary cortical projection site of the olfactory bulbs. The current study used BrdU-injection paradigms, and in vivo and in vitro DiI tracing methods to address three fundamental issues of these cells: their origin, migratory route and fate. The results show that 1 day after a BrdU-injection, BrdU/DCX double-labeled cells appear deep to the ventricular subependyma, within the white matter. Such cells appear further ventral and caudal in the ensuing days, first appearing in the rostral piriform cortex of mice at 2 days after the BrdU-injection, and at 4 days in the rat. In the caudal piriform cortex, BrdU/DCX labeled cells first appear at 4 days after the injection in mice and 7 days in rats. The time it takes for these cells to appear in the piriform cortex and the temporal distribution pattern suggest that they migrate from outside this region. DiI tracing methods confirmed a migratory route to the piriform cortex from the ventricular subependyma. The presence of BrdU/NeuN labeled cells as early as 7 days after a BrdU injection in mice and 10 days in the rat and lasting as long as 41 days indicates that some of these cells have extended survival durations in the adult piriform cortex.


Subject(s)
Cell Differentiation , Cell Lineage , Cell Movement , Neurons/physiology , Olfactory Bulb/physiology , Olfactory Pathways/physiology , Animals , Animals, Newborn , Bromodeoxyuridine , Carbocyanines , Cell Shape , Cell Survival , DNA-Binding Proteins , Doublecortin Domain Proteins , Doublecortin Protein , Fluorescent Dyes , Ki-67 Antigen/analysis , Male , Mice , Microscopy, Confocal , Microscopy, Immunoelectron , Microtubule-Associated Proteins/analysis , Nerve Tissue Proteins/analysis , Neurons/chemistry , Neuropeptides/analysis , Nuclear Proteins/analysis , Olfactory Bulb/chemistry , Olfactory Bulb/cytology , Olfactory Pathways/chemistry , Olfactory Pathways/cytology , Rats , Rats, Sprague-Dawley , Staining and Labeling/methods , Time Factors
9.
Neuroreport ; 18(10): 981-5, 2007 Jul 02.
Article in English | MEDLINE | ID: mdl-17558281

ABSTRACT

Neurogenesis persists in the adult rodent olfactory epithelium and olfactory bulbs. Recent studies suggest that neurogenesis might also occur in the adult rodent piriform cortex, the primary cortical projection site of the olfactory bulbs. To determine whether olfactory enrichment influences neurogenesis in the mouse piriform cortex, olfactory enrichment was used in combination with bromodeoxyuridine labeling. Quantification of the number of bromodeoxyuridine-labeled cells in the piriform cortex that double label for either the immature neuronal marker, doublecortin, or the mature neuronal marker, neuronal nuclei or NeuN, showed that olfactory enrichment increases the survival of newborn neurons in the piriform cortex. These results confirm that neurogenesis occurs in the piriform cortex of rodents and suggest that it may play a neuroplastic role there.


Subject(s)
Cerebral Cortex/cytology , Neurons/physiology , Odorants , Olfactory Pathways/physiology , Organogenesis/physiology , Animals , Brain Mapping , Bromodeoxyuridine/metabolism , Cell Count/methods , Cell Differentiation/physiology , Doublecortin Domain Proteins , Mice , Mice, Inbred C57BL , Microtubule-Associated Proteins/metabolism , Neuropeptides/metabolism , Olfactory Bulb/physiology , Phosphopyruvate Hydratase/metabolism , Time Factors
10.
J Biol Chem ; 282(10): 6917-21, 2007 Mar 09.
Article in English | MEDLINE | ID: mdl-17259180

ABSTRACT

Prokineticin 2, a cysteine-rich secreted protein, regulates diverse biological functions including the neurogenesis of olfactory bulb. Here we show that the PK2 gene is a functional target gene of proneural basic helix-loop-helix (bHLH) factors. Neurogenin 1 and MASH1 activate PK2 transcription by binding to E-box motifs on the PK2 promoter with the same set of E-boxes critical for another pair of bHLH factors, CLOCK and BMAL1, in the regulation of circadian clock. Our results establish PK2 as a common functional target gene for different bHLH transcriptional factors in mediating their respective functions.


Subject(s)
Basic Helix-Loop-Helix Transcription Factors/physiology , Gastrointestinal Hormones/genetics , Neuropeptides/genetics , Olfactory Bulb/physiology , Animals , Basic Helix-Loop-Helix Transcription Factors/genetics , Cell Differentiation , Cell Movement , Gene Expression Regulation , Mice , Nerve Tissue Proteins/physiology , Promoter Regions, Genetic , Stem Cells/cytology
11.
Science ; 308(5730): 1923-7, 2005 Jun 24.
Article in English | MEDLINE | ID: mdl-15976302

ABSTRACT

Neurogenesis persists in the olfactory bulb (OB) of the adult mammalian brain. New interneurons are continually added to the OB from the subventricular zone (SVZ) via the rostral migratory stream (RMS). Here we show that secreted prokineticin 2 (PK2) functions as a chemoattractant for SVZ-derived neuronal progenitors. Within the OB, PK2 may also act as a detachment signal for chain-migrating progenitors arriving from the RMS. PK2 deficiency in mice leads to a marked reduction in OB size, loss of normal OB architecture, and the accumulation of neuronal progenitors in the RMS. These findings define an essential role for G protein-coupled PK2 signaling in postnatal and adult OB neurogenesis.


Subject(s)
Cerebral Ventricles/physiology , Gastrointestinal Hormones/metabolism , Interneurons/physiology , Neurons/physiology , Neuropeptides/metabolism , Olfactory Bulb/cytology , Olfactory Bulb/metabolism , Signal Transduction , Stem Cells/physiology , Animals , Apoptosis , Brain/cytology , Brain/growth & development , Brain/metabolism , Cell Adhesion , Cell Count , Cell Line , Cell Proliferation , Cerebral Ventricles/cytology , Chemotactic Factors/physiology , Chemotaxis , Coculture Techniques , Dopamine/physiology , Gene Expression , Interneurons/cytology , Mice , Mice, Inbred C57BL , Neurons/cytology , Olfactory Bulb/growth & development , Rats , Rats, Sprague-Dawley , Receptors, G-Protein-Coupled/genetics , Receptors, G-Protein-Coupled/metabolism
12.
Int Immunol ; 16(12): 1789-98, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15520044

ABSTRACT

The signaling enzyme phosphoinositide 3-kinase (PI3K) is activated following B cell receptor (BCR) engagement and by many other receptors on B lymphocytes. Mice lacking p85alpha, the predominant PI3K regulatory isoform, exhibit defects in B cell development and activation that are grossly similar to those found in mice lacking Bruton's tyrosine kinase (Btk) and other critical signaling molecules. However, a detailed analysis of splenic B cell subsets in p85alpha-deficient mice has not been reported. Here we show that these mice are deficient in four major B cell subsets: transitional-1, transitional-2, follicular and marginal zone. These defects are distinct from those observed in Xid mice that express a mutant Btk unable to interact with PI3K lipid products. Moreover, mice with both genetic lesions exhibit even greater impairment in B cell development. Finally, we show that transgenic expression of the anti-apoptotic protein Bcl-2 in p85alpha-deficient mice restores the transitional B cell subsets but not the marginal zone subset, and produces a follicular population with an aberrant phenotype. These findings establish a role for PI3K-p85alpha in differentiation of both follicular and marginal zone B cells, and suggest that these functions are required not solely for the propagation of anti-apoptotic signals.


Subject(s)
B-Lymphocyte Subsets/enzymology , Lymphocyte Activation/physiology , Phosphatidylinositol 3-Kinases/physiology , Proto-Oncogene Proteins c-bcl-2/physiology , Spleen/immunology , Agammaglobulinaemia Tyrosine Kinase , Animals , Apoptosis , B-Lymphocyte Subsets/cytology , B-Lymphocyte Subsets/metabolism , Cell Differentiation/genetics , Cell Differentiation/physiology , Gene Expression , Isoenzymes/genetics , Isoenzymes/physiology , Lymphocyte Activation/genetics , Mice , Mice, Transgenic , Mutation/genetics , Phosphatidylinositol 3-Kinases/genetics , Protein-Tyrosine Kinases/genetics , Proto-Oncogene Proteins c-bcl-2/genetics , Signal Transduction/genetics , Signal Transduction/physiology , Spleen/cytology , Transgenes/genetics , Transgenes/physiology
13.
Eur J Immunol ; 34(11): 2968-76, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15384044

ABSTRACT

Phosphoinositide 3-kinase (PI3K) is a ubiquitously expressed signaling enzyme that plays an integral role in development and activation of B cells. B cell receptor (BCR)-driven proliferation is completely blocked either in cells lacking the p85alpha regulatory isoform of PI3K or in wild-type cells treated with pharmacological PI3K inhibitors. However, the contribution of p85alpha to early signaling events has not been fully investigated. Here we show that B cells lacking p85alpha have signaling impairments that are both quantitatively and qualitatively different from those in cells treated with PI3K inhibitors. Loss of p85alpha results in partial reductions in Ca2+ mobilization and IkappaB phosphorylation, whereas ERK phosphorylation is not diminished. Moreover, although Akt phosphorylation is partially reduced, phosphorylation of several proteins downstream of Akt is preserved. These partial impairments suggest that there are other routes to PI3K activation in B cells apart from p85alpha-associated catalytic subunits. Notably, addition of phorbol ester restores BCR-mediated proliferation in p85alpha-deficient cells but not wild-type cells treated with PI3K inhibitors. These findings suggest that the primary BCR signaling defect in B cells lacking p85alpha is a failure to activate diacylglycerol-regulated signaling enzymes, most likely protein kinase C.


Subject(s)
B-Lymphocytes/immunology , Phosphatidylinositol 3-Kinases/immunology , Animals , B-Lymphocytes/cytology , B-Lymphocytes/enzymology , Calcium/immunology , Cell Proliferation , Enzyme Activation/immunology , Enzyme Inhibitors/pharmacology , Flow Cytometry , I-kappa B Proteins/immunology , Isoenzymes , Lymphocyte Activation/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Mitogen-Activated Protein Kinase 3/immunology , NF-KappaB Inhibitor alpha , Phosphatidylinositol 3-Kinases/deficiency , Phosphoinositide-3 Kinase Inhibitors , Phosphorylation , Protein Serine-Threonine Kinases/immunology , Proto-Oncogene Proteins/immunology , Proto-Oncogene Proteins c-akt , Receptors, Antigen, B-Cell/immunology , Signal Transduction/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...